EUVIMEDEUVIMED entdecken
Crossref

Exploring Pristinamycin‐Derived Natural Compounds as Inhibitors of SARS‐CoV‐2 Replication Enzymes

Mohammad Nur‐e‐Alam, Sarfaraz Ahmed, Adnan J. Al‐Rehaily, Mohammad K. Parvez, Morooj A. Alharbi, Altaf Khan

ChemistrySelect · 2026-11 · 11 (43)

DOI: 10.1002/slct.75087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 16.11.2026. Verfasst von Mohammad Nur‐e‐Alam und 5 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS‐CoV‐2 continues to pose a global health threat, with successive variants of concern progressively undermining existing treatments and reinforcing the demand for new antiviral strategies. Natural products, valued for their structural diversity and multitarget potential, represent a promising reservoir for antiviral drug discovery. The present study evaluated five bioactive compounds from Streptomyces pristinaespiralis as potential inhibitors of two essential viral enzymes, Mpro, a clinically validated drug target, and nsp13 helicase, which is highly conserved across SARS‐CoV‐2 variants, using a structure‐based computational approach. The selected compounds were docked to the active sites of both target proteins using Glide SP, followed by all‐atom molecular dynamics simulation for 200 ns to assess the structural stability and interaction dynamics of the best‐ranked ligand–protein complexes. STR‐15 showed the highest binding affinity toward Mpro with docking score −7.9 kcal/mol, STR‐9 showed the best binding to nsp13 with docking score −10.0 kcal/mol. The two ligands interacted with the catalytically relevant residues through hydrogen bonding, hydrophobic interactions and π‐interactions, supporting their potential as lead compounds for the studied targets. Molecular dynamics analysis over 200 ns confirmed the persistence of key interactions and structural integrity, with ligand RMSD of ∼2.0–2.5 Å featuring stable binding. While these results are inherently predictive in nature, they provide a well‐founded basis for prioritizing these compounds for future experimental validation, including in vitro enzymatic inhibition assays and cell‐based antiviral screening.

Zitieren

APA

Nur‐e‐Alam, M., Ahmed, S., Al‐Rehaily, A. J., Parvez, M. K., Alharbi, M. A., & Khan, A. (2026). Exploring Pristinamycin‐Derived Natural Compounds as Inhibitors of SARS‐CoV‐2 Replication Enzymes. ChemistrySelect, 11(43). https://doi.org/10.1002/slct.75087

Vancouver

Nur‐e‐Alam M, Ahmed S, Al‐Rehaily AJ, Parvez MK, Alharbi MA, Khan A. Exploring Pristinamycin‐Derived Natural Compounds as Inhibitors of SARS‐CoV‐2 Replication Enzymes. ChemistrySelect. 2026;11(43). doi:10.1002/slct.75087

BibTeX
@article{NureAlam2026,
  author = {Nur‐e‐Alam, Mohammad and Ahmed, Sarfaraz and Al‐Rehaily, Adnan J. and Parvez, Mohammad K. and Alharbi, Morooj A. and Khan, Altaf},
  title = {Exploring Pristinamycin‐Derived Natural Compounds as Inhibitors of SARS‐CoV‐2 Replication Enzymes},
  journal = {ChemistrySelect},
  year = {2026},
  volume = {11},
  number = {43},
  doi = {10.1002/slct.75087}
}
Kostenlos starten →